Anupam Rasayan open offer for Bliss GVS Pharma at Rs 299 per share

Listed Co AcquisitionOpen Offer TriggeredStrategic Transactions View source PDF Explain this filing

ANURAS · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reactionminutes from the announcement price · days from the prior close

-1.1%Reaction day

₹1266.20

prior close

₹1272.00

announcement price

After-mkt

timing

Nifty Smallcap 250market-1.3%+0.2% vs market

Specialty Chemicals peers, median of 94sector-0.9%-0.2% vs sector

On the reaction day the stock moved 0.2 pts more than Nifty Smallcap 250 and 0.2 pts less than its Specialty Chemicals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.

Minutes after the announcementfrom the announcement price · no benchmark

Stock

-0.5

10m

-0.4

15m

-0.5

30m

-0.5

Sessions after the filingfrom the prior close

StockMarketvs marketSectorvs sector

Reaction day

-1.1-1.3+0.2-0.9-0.2

Next day

-1.8-2.5+0.7-1.8+0.0

-2.5-2.8+0.3-2.1-0.3

-3.9-1.5-2.4-0.5-3.4

-3.6-2.0-1.6-1.3-2.3

-4.1-0.7-3.4-0.6-3.5

-4.8-1.0-3.8-1.5-3.2

15d

-5.1+1.3-6.4+1.9-7.0

-0.8+1.5-2.4+1.2-2.0

-4.9+0.9-5.8+1.6-6.5

-13.0-6.9-6.2-3.2-9.8

UpDownMarket · Nifty Smallcap 250Sector · Specialty Chemicals peers, median of 94Pending

Minute windows have no benchmark: there is no intraday index history to compare against.

AI summary

Anupam Rasayan India, along with PAC Mates Visa Consultancy, is making a cash open offer to acquire up to 2.77 crore equity shares (26% of expanded voting share capital) of Bliss GVS Pharma at Rs 299 per share. Total consideration is about Rs 829 crore assuming full acceptance. The tender period runs from 28 July to 10 August 2026. The offer is triggered under SEBI takeover rules following a Share Purchase Agreement with existing promoters and certain shareholders of Bliss GVS Pharma.

Likely market impact

Bliss GVS public shareholders get an exit opportunity at Rs 299 per share. Anupam Rasayan is expanding into pharma via acquisition of a listed company.